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Abstract	  
	  
Inflammation is an important underlying biochemical process of many fatal 
diseases and infections. Inflammation can be an acute response to trauma or infection, or 
chronic in cardiovascular diseases like atherosclerosis. In the United States, in 2011 
atherosclerosis was responsible for 16% of all deaths, and in 2015 an estimated 200,000 
people will die from sepsis [1, 2]. The Cardiovascular Health Study (CHS) found that 
elevated plasma concentration of the inflammatory protein soluble CD14 (sCD14) 
independently predicts mortality from atherosclerotic cardiovascular diseases in older 
adults [3]. Genomewide SNPs explained approximately 33% of the sCD14 phenotypic 
variance. In European Americans, the strongest genome-wide association signal was 
centered around the CD14 structural gene [3], yet little is known about how these SNPs 
affect the circulating plasma sCD14 that was measured by ELISA in this study. We 
therefore sought to determine if different forms of sCD14, as measured by the ELISA in 
the CHS, could be detected in a small (N=15), presumably healthy human population. 
Utilizing gel filtration column chromatography to estimate molecular weights 
(MWs), sCD14 was detectable over a spectrum of MWs from 20kDa to 150kDa, and had 
an approximate peak around 55kDa. These data support previous research suggesting that 
there are multiple forms of sCD14 in human plasma. It appears that the ELISA is not 
detecting sCD14 on microparticle or a 13kDa fragment (sCD14-ST). There does appear 
to be a higher MW sCD14 form that seems to be primarily detectable between 71kDa to 
87kD. A sCD14 form in this MW range has never been described in the literature. In 
order to describe the different sCD14 MW variants, further inquiry is needed into the 
precise MWs of each form of sCD14 in plasma. 
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Introduction 
Our immune system is constantly detecting and responding to pathogens and 
stressors. The innate immune system provides the first, rapid inflammatory response. 
These inflammatory immune responses are critical to our survival, and paradoxically 
seem to have both protective and damaging effects. CD14 has emerged as an important 
molecule in the activation of the innate immune system [3, 4]. 
 First discovered and classified in 1982, human CD14 is a pattern recognition 
receptor that helps activate the innate-immune system in response to infection and in 
chronic inflammatory diseases [3, 5, 6]. CD14 is a single-polypeptide glycoprotein found 
in various soluble forms (sCD14), and constitutively on the membrane (mCD14) of 
monocytes, neutrophils, macrophages and on some hepatocytes, via a 
glycosylphosphatidylinositol (GPI) linkage [3]. Additionally, mCD14 expression has 
been observed on oral, corneal, and skin epithelia [6]. There is a strong positive 
association observed between the total sCD14 concentration in plasma and 
atherosclerosis in older adults, and several studies demonstrated total sCD14 levels rise 3 
to 5 times higher in patients of severe trauma, infection, toxic shock (sepsis), acquired 
immunodeficiency syndrome (AIDS), and several other diseases when compared to 
healthy controls [3, 7, 8].  
The Different Forms of CD14 
 Different forms of sCD14 have been previously measured in various 
human fluids in the range of 41-57kDa [9-11], and in monocytes the mCD14 form has 
been consistently measured around 55kDa [12]. Previous information regarding the 
different forms of sCD14 come from numerous in vitro experiments that isolated CD14 
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from Chinese Hamster Ovary (CHO) Mono-Mac-6 cell lines, human monocytes, and 
human plasma and sera samples. The current working hypothesis is that there are at least 
4 different mechanisms by which sCD14 could be released from monocytes (Figure 1). 
 
Figure 1: 4 theoretical mechanisms of release from a human monocyte of soluble 
CD14 (sCD14), sCD14-sub-type (sCD14-ST), and sCD14 on microparticles or 
exosome. A 50kDa, common precursor form of both membrane CD14 (mCD14) 
and sCD14 is shown. Mechanism I is the proteolytic and/or enzymatic cleavage of 
mCD14 which forms higher and lower molecular forms of sCD14, including the 
highly truncated sCD14-ST form. Mechanism II involves the release of CD14 as a 
microparticle or exosome. Mechanism III is the direct secretion of sCD14 without 
attachment to the membrane, accounting for both low and high molecular weight 
forms. Mechanism IV is the variation of glycosylation, accounting for a spectrum 
of both low and high molecular weight forms. Adapted from Jack R.S. [13] 
 
Mechanism I is the lipolytic or proteolytic cleavage of CD14 at various peptide 
locations. Lipolytic cleavage would occur at the GPI moiety that extracellularly anchors 
mCD14 and protyeolsis could occur at varoius amino acid locations on mCD14 or 
sCD14. Different proteolytic sites may partly explain why CD14 has been measured in 
forms as high as 57kDa and in lower MWs around 13kDa (sCD14-ST). The mCD14 GPI-
anchor could be directly cleaved by phospholipase C or D or cleaved off entirely by a 
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cell-surface serine or aspartate protease [14]. Phospholipase cleavage is a common 
mechanism for other GPI-linked proteins and would result in a slightly larger sCD14 
isoform than cleavage by a protease, due to the remaining inositol moiety group [4, 14, 
15]. The 13kDa subtype-form, sCD14-ST (also called Presepsin), is a 65-amino acid 
peptide fragment of the N-terminus of sCD14 [16]. The current hypothesis is that sCD14-
ST is formed from the cleavage of sCD14 by a plasma protease, most likely an aspartate-
protease [17, 18].  
Mechanism II is a process involving exocytosis of CD14 as a microparticle or 
exosome. It has been suggested that both sCD14 and mCD14 could be released as 
exosomes from activated monocytes following post-translational modification of a 50kDa 
CD14 precursor peptide [19, 20]. Although not described, apoptosing monocytes could 
also release mCD14 on a lipid microparticle [20, 21]. CD14 associated with a 
microparticle would be detectable at very high MWs, whereas CD14 released within an 
exosome should not be detectable.  
Mechanism III describes the release of sCD14 due to a missing or non-functional 
C-terminal, GPI anchoring sequence. CD14 cannot become mCD14 if the anchoring 
sequence is non-functional or absent. In vitro studies demonstrate that CD14 with a non-
functional or absent anchoring sequence can be directly secreted as sCD14 [22].  
Mechanism IV would account for the spectrum of sCD14 MW forms as high as 
57kDa and as low as a 41kDa, as a function of different levels of glycosylation. In one 
study, sCD14 was detected approximately around 55kDa, but after removal of sugars 
from both N and O glycosylation sites, sCD14 was detected at approximately 46kDa and 
43kDa in the supernatant of CHO cell lysates. The de-glycosylated forms bound to 
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Lipopolysaccharide (LPS), but the regulatory effects of glycosylation on CD14 are 
unknown in vivo [22].  
In summary, it is expected that CD14 could be detected in various forms in 
plasma. Glycosylation [23] and different cleavage forms [14] could result in fragments as 
low as 13kDa (sCD14-St), and account for a range up to 41kDa to 57kDa. CD14 could 
also be in an exosome or attached to microparticle [20].  
Biochemical Pathways of CD14 
CD14 is a nonspecific scavenger that presents antigens to trans-membrane 
extracellular receptors. Once activated, these trans-membrane receptors modulate 
complex intracellular pathways that control the specific type of immune response [24]. 
As a pattern-recognition receptor of the innate immune system, CD14 binds to gram 
positive and negative bacteria, non-microbial molecules and other acylated ligands [4, 
25]. The most studied ligand of CD14 is lipopolysaccharide (LPS), also called Endotoxin, 
a characteristic surface antigen of gram-negative bacteria. The interaction of CD14 with 
LPS is an important process for the rapid synthesis of cytokines and chemokines of the 
innate immune response and other molecules that can activate the adaptive immune 
response [11, 25].  
The soluble and membrane forms of CD14 perform the scavenging and transfer to 
the toll-like-receptor (TLR) complexes slightly differently but with similar downstream 
effects. The mCD14 aggregates with TLR via lipid rafts, while sCD14 binds to available 
TLRs on both mCD14 and non non-mCD14 expressing cells [26].  
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CD14 in Disease 
Acute and intense activation of the TLR4 pathway by high concentrations of LPS 
is one mechanism that can lead to systemic inflammation and sepsis [27, 28]. Sepsis is a 
complex process involving both hyper and anti-inflammatory responses [28, 29]. The 
hyper-inflammatory process of sepsis seems to involve the significant increase in plasma 
cytokines, tumor necrosis factor-alpha (TNF- α) and other inflammatory molecules 
including sCD14-ST [28]. Within the last several years, the quantification of plasma 
sCD14-ST concentration has been used clinically for the early diagnosis of septic shock.  
The activation of TLR-4 by sCD14 in non-myeloid cells, particularly in smooth 
endothelial and muscle cells, seems to have an important role in the atherosclerotic 
disease process [3, 30]. Plasma sCD14 was measured in the CHS, a prospective study of 
cardiovascular disease in more than 5,000 adults aged 65 and older [3]. The CHS data 
show that plasma sCD14 concentrations independently predicted mortality and correlated 
with many other acute-phase proteins and several single-nucleotide polymorphisms 
(SNPs) related to CD14 production and within the CD14 structural gene. One SNP of 
particular interest is a missense variant SNP in the gene that codes for 
Phosphatidylinositol N-acetylglucosaminyltransferase subunit C (PIGC). PIGC is one of 
three genes that mediate GPI-anchor biosynthesis. The PIGC SNP rs063412 was 
associated with higher sCD14 concentrations in European Americans (P<5×10−8) [3]. As 
predicted by mechanism III, plasma sCD14 concentrations could be increased by 
disruption of GPI-anchor biosynthesis, which may have implications for chronic 
inflammatory processes [22].  
Munger	   8	  
CD14 has been identified as a potential therapeutic target. Early-phase animal 
studies have shown promise in treating sepsis with anti-CD14 antibodies [31, 32]. 
Understanding sCD14 MW variants might help target specific, more effective treatments. 
 
Materials and Methods: 
 
Whole Blood Collection and Preparation: 
 Following IRB-approval, CHRMS 05-039, blood was collected from 15 
presumably healthy volunteers into heparin-coated tubes to prevent clotting. Each sample 
was centrifuged to remove cells, and 1 mL plasma aliquots were stored at -800C. Plasma 
samples were thawed at 370C in an agitated water bath prior to use. All samples were de-
identified. 
Size Exclusion Chromatography 
 Plasma was separated by MW over a pre-packed HiPrep 16/60 Sephacryl S200 
size-exclusion column (Pharmacia S200). The column was run in 10mM ammonium 
acetate buffer, pH 7.0 at a flow rate of 0.5 mL/min, using a 1 ml injection loop and a 
Pharmacia FPLC system. The ammonium acetate buffer was chosen because it is a 
volatile buffer, which allows for future lyophilization if necessary (freeze-drying) to 
increase protein concentration.  
The Pharmacia S200 column separates protein complexes between 5KDa and 
200KD, an appropriate MW range to separate sCD14 and plasma proteins [33]. 
Complexes elute off the column in decreasing size. Small molecules get trapped in the 
pores on beads, while larger molecules pass around the beads. Very large molecules 
(>200kD) are not included in the beads and elute from the column first, after about a third 
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of column-volume of buffer is run. This is called the void volume, and was determined 
using blue dextran, a 2,000kDa molecule [34].  
The column was cleaned with ethanol and sodium hydroxide, and validated using 
single-peptide, globular proteins standards of the following MWs: 13kDa, 29kDa, 44kDa 
and 75kDa (GE Healthcare Life Sciences). A best-fit linear calibration equation was 
calculated from a plot of the log-transformed elution volume of each protein to its 
corresponding log transformed molecular weight (Figure 2), and this was used to estimate 
the molecular weights of proteins found in specific elution volumes from the column.  
 
Figure 2. Molecular weight standard curve and linear equation. Approximate molecular weights 
were experimentally determined by running Gel Filtration Calibration kits (GE Healthcare Life 
Sciences). The recombinant proteins Conalbumin (75kDa), Ovalbumin (43kDa), Carbonic 
anhydrase (29kDa), and Ribonuclease (13.7kDa) were run over the column and plotted. 
Absorbance at 280 nm was measured using a Nanodrop spectrophotometer and peaks were 
identified. The log transformed elution volumes correspond to the log-transformed known 
molecular weight of the recombinant proteins and the void volume (220kDa). 
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280nm Nanodrop Spectrophotometry 
 Following fractionation by column chromatography, 10uL aliquots of each 
fraction were analyzed by 280nm spectrophotometry (Nanodrop® -1000). Protein 
spectrophotometry is based on the detection of peptides with aromatic side chains, which 
absorb UV light at a 280nm wavelength [35]. Even though proteins have different 
compositions of aromatic peptides, 280nm spectrophotometer provides an estimate of 
total protein concentration. This technique was used to assess if each plasma sample had 
typical protein profile and eluted off the column in the expected fractions.  
Enzyme-Linked Immunosorbent Assay (ELISA) 
 Samples were thawed for 15 minutes in a 37oC agitated water bath, and the 
original plasma sample and the odd column fractions were analyzed by solid phase 
sandwich CD14 ELISA (R&D Systems, Minneapolis MN). This ELISA kit was selected 
because it was previously used to analyze total plasma sCD14 in the CHS [3]. Following 
manufacturer’s directions, column fractions were diluted 10-fold, and plasma samples 
were diluted 200-fold to ensure measurements were within the dynamic range of the 
standard curve [36]. The ELISA has 96 wells coated with a capture antibody. A 
secondary, enzyme-linked polyclonal antibody binds the immobilized sCD14 and part of 
the primary antibody, “sandwiching” the CD14 protein. A substrate solution is then 
added, which is cleaved by the enzyme on the secondary antibody to produce a colored 
reaction product over a 30-minute period. The reaction is halted and a plate reader is used 
to measure the 450nm absorbance of the wells. The concentration of individual wells is 
extrapolated from a standard curve based on a recombinant CD14 standard (Figure 3).  
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Figure 3. sCD14 standard curve measured by ELISA (R&D Systems, Minneapolis, MN). 
For each ELISA plate a recombinant human CD14 was serially diluted and measured in 
duplicate in order to create a standard curve and equation to estimate sample sCD14 
concentration.  
Data Analysis 
The sCD14 in the starting plasma of the 15 samples was compared to previously 
reported values from the CHS cohort. The percent recovery of sCD14 in the fractions was 
calculated for each donor. Donors exhibiting atypical total protein profiles were 
identified. The symmetry, width, height and notable characteristics of the sCD14 profile 
of different donors were assessed visually and in relation to the MW standard curve. The 
variation at different MW regions between donors was assessed by combining the mean 
protein and sCD14 concentrations of regions of elution volumes into “bins”. Elution 
volumes were excluded from analysis if more than 2 samples did not have sCD14 
measurements or had a measured sCD14 concentration of 0.0ng/mL. Included fractions 
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were grouped into 6 bins representative of the combined sCD14 profile of all donors. The 
mean, median, standard deviation (SD) and coefficient of variation (CV) of total protein 
and sCD14 concentrations were calculated for each bin. The Brown–Forsythe test, a 
method that compares the absolute deviations from the median of different empirical 




In each donor total protein was measured in all elution volumes, and sCD14 was 
measured in odd elution volumes and in the starting plasma sample. The sCD14 
concentration in plasma from all 15 donors had a median of 1581ng/mL and a mean±SD 
of 1680 ±339ng/mL. These results are comparable to CHS findings that observed a 
mean±SD sCD14 concentration of 1641±348ng/mL in over 5,000 individuals using the 
same ELISA [3].  
The fractionation of total protein in each donor was compared before analyzing all 
of the sCD14 profiles in relation to each other. There was a typical pattern of protein 
separation into 3-peaks (Figure 4). The first peak on the left represents the void volume, 
containing all of the plasma proteins with a 200kDa MW and higher, such as fibrinogen 
and alpha-2 macroglobulin. The second peak also contains many proteins, including IgG, 
and the last peak is primarily albumin. Two donors exhibited atypical total protein 
fractionation profiles (Figure 4). Each of these 2 donors had abnormally reduced peaks in 
the void volume, which contains fibrinogen, and the peak where IgG are typically 
observed. These	  atypical	  protein	  profiles	  are	  likely	  a	  direct	  result	  of	  activation	  of	  coagulation	  during	  phlebotomy	  due	  to	  poor	  mixing	  of	  the	  blood	  with	  the	  heparin	  anti-­‐coagulant	  or	  cryo-­‐precipitation	  due	  to	  non-­‐standardized	  thawing	  techniques.	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FIGURE 4. Individual fractions of human plasma separation with total protein concentration. For 
each donor, 1 ml of human plasma was run over a S200 column in Ammonium Acetate Buffer, pH 7.0. 
The first 30 ml of buffer were discarded and 1 ml fractions were collected for the next 96 mLs and 
Absorbance at 280 nm was measured using a Nanodrop Spectrophotometer. Approximate molecular 
weights (Blue arrow MWs=75, 44, 29, 13.7kD respectively) were determined by running Gel 
Filtration Calibration kits (GE Healthcare Life Sciences) and calculating a standard curve. 2 Donors 
with atypical 280nm spectrophotometry are highlighted in yellow and orange. 
 
The sCD14 profiles of each donor exhibiting abnormally reduced peaks were 
visually assessed in comparison to all other donors for observable trends (Figure 6). 
Notable differences in sCD14 profiles were not observed between donors with atypical 
and typical total protein fractionation profiles. However, because the atypical-protein 
profiles could have some unknown effect on the sCD14 pool, the 2 atypical donors were 
excluded, leaving 13 samples for further analysis. 
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A pseudo-integral of each sCD14 fractionation curve was used to estimate total 
sCD14 measured in the elution volumes of each donor. A percent recovery from plasma-
measured sCD14 was calculated for each donor (Table 1). Recovery ranged from 39.2% 
to a high of 102%, indicating a wide range of assay variability and technical error.  
Recovery	  of	  sCD14	  in	  Chromatography	  Fractions	  
Donor	  ID	   Percent	  Recovery	  
2	   58.72	  
3	   39.21	  
4	   82.02	  
5	   83.06	  
6	   102.38	  
7	   76.41	  
8	   68.74	  
9	   62.94	  
10	   62.46	  
11	   70.93	  
12	   99.39	  
16	   57.22	  
17	   75.62	  
18	   77.49	  
19	   88.78	  
Table 1. Total sCD14 measured in the fractions was estimated by taking an 
approximate integral of the sCD14 curve of each donor. The sCD14 measured in 
total plasma was used as a denominator.  	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Slight	  variation	  between	  chromatography	  separations	  could	  introduce	  apparent	  differences	  between	  donors.	  Therefore,	  the	  sCD14	  profiles	  of	  donors	  with	  280nm	  absorbance	  profiles	  that	  appeared	  to	  elute	  off	  at	  the	  column	  at	  different	  times	  were	  compared	  with	  a	  dual axis graph (Figure	  5). A dual axes is necessary 
because plasma protein concentration is more than 1000 times higher than sCD14 
concentration.	  Even	  when	  comparing	  the	  2	  samples	  with	  the	  largest	  difference	  in	  the	  location	  of	  the	  void	  volume,	  no	  clear	  trend	  was	  observed	  between	  donors	  with	  a	  later	  280nm	  absorbance	  profile	  and	  a	  later	  sCD14	  peak	  (Figure	  5).	  	  
	  
FIGURE 5. Human Plasma Separation highlighting potential differences between 
chromatography separation. In terms of 280nm absorbance, donor 10 (green) seems to elute 
off the column before donor 7(orange). However, in terms of sCD14 concentration, donor 10 
seems to have a slightly later sCD14 peak than donor 7. For each donor, 1 ml of human 
plasma was run over a S200 column in Ammonium Acetate Buffer, pH 7.0. The first 30 ml of 
buffer were discarded and 1 ml fractions were collected for the next 96 mLs and Absorbance 
at 280 nm was measured using a Nanodrop Spectrophotometer. The odd fractions were 
analyzed for the presence of sCD14 by ELISA (R&D Systems, Minneapolis MN) according to 
manufacturer instructions. Approximate molecular weights (Blue arrow MWs=75, 44, 29 and 
13.7kD respectively) were determined by running Gel Filtration Calibration kits (GE 
Healthcare Life Sciences). 
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The fractionated profiles of total protein concentration and sCD14 concentration 
of each donor were graphed together. Donors with notably different sCD14 profiles were 
compared (Figure 6). In addition to the common peak around 55kDa, shoulders were 
often present, most notably on the left side, and less prominently on the right side of the 
sCD14 peak in many donors (Figure 6). 
 
FIGURE 6. Human Plasma Separation highlighting differences between 2 donors and common 
characteristics among all donors. Donor 2 (red) and donor 6 (blue) have notable “shoulders” on the 
higher MW side of the peak. Donor 2 has a shoulder on the lower MW side of the peak. For each 
donor, 1 ml of human plasma was run over a S200 column in Ammonium Acetate Buffer, pH 7.0. The 
first 30 ml of buffer were discarded and 1 ml fractions were collected for the next 96 mLs and 
Absorbance at 280 nm was measured using a Nanodrop Spectrophotometer. The odd fractions were 
analyzed for the presence of sCD14 by ELISA (R&D Systems, Minneapolis MN) according to 
manufacturer instructions. Approximate molecular weights (Blue arrow MWs=75, 44, 29, 13.7kD 
respectively) were determined by running Gel Filtration Calibration kits (GE Healthcare Life 
Sciences). 
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Among the 13 donors included in the analysis, there were some notable 
similarities and differences between the sCD14 profiles. These phenotypes were 
evaluated in relationship to approximate MW markers from the standard equation. 
Twelve donors had 1 clearly distinct peak. In 5 samples, the sCD14 peak was at the 
63mL elution volume, which corresponds to 52.5kDa, and in the other 7 samples the peak 
occurred at the 61mL elution volume, which corresponds to a MW of 59kDa. One sample 
exhibited 2 distinct peaks, occurring at elution volumes 59mL and 63mL, which 
correspond to 67kDa and 52.5kDa respectively. A salient characteristic of the sCD14 
profile was 1 or 2 shoulders on the either side of the peak. In 10 donors, shoulders on the 
higher MW side were observed between the approximate MW of 71.5kDa and 134.5kDa. 
In 6 donors there was a shoulder between 71.5kDa and 87kDa. Two donors with main 
peaks at 59kDa had 2 shoulders on the left side of the peak; the first higher MW peak 
corresponded to approximately 116kDa in both donors, and the second higher MW peak 
was observed at 87kDa and 76kDa. Shoulders on the lower MW side of the peak were 
also observed in 7 donors. A closer shoulder was present at approximately 46.5kDa in 4 
of the donors, 41.5kDa in 1 donor and around 30kDa in 1 donor. The very low molecular 
weight shoulder was present around 27kDa in 2 donors, 25kDa in 1 donor, and 20.5kDa 
in 1 donor. The 3 donors without shoulders had 1 clearly distinct, symmetrical peak at the 
elution volume corresponding to approximately 59kDa. In general, some donors had 
much wider profiles that spanned more elution volumes, suggesting that these donors had 
a broader range of different MW forms than others. Based on running samples in 
singleton and only measuring odd fractions, major differences in the sCD14 profiles, in 
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particular the presence of shoulders and multiple peaks, suggests that the relative 
quantities of different MW forms varies more between some donors. 
All 15 sCD14 profiles were graphed together, allowing for a general assessment 
of the sCD14 profile of all typical donors in relation to the donors with likely non-
standardized sample handling (Figure 7). The sCD14 was typically first detected in 
elution volumes that corresponded to very high molecular weights (>150kDa), and 
gradually increased with a variable slope to a peak corresponding to an approximate 
molecular weight of 55kDa (Figure 7). In all donors, the left side of the sCD14 peak 
overlapped with right side albumin peak. In general, there seemed to be an asymmetrical 
sCD14 peak and sCD14 concentrations decreased steeply and consistently after the peak 
in all donors. By the elution volumes corresponding to approximately 30kDa, sCD14 was 
weakly detectable. There was no sCD14 detectable in any donor at the elution volume 
corresponding to approximately 13kDa, suggesting that sCD14-ST is not detected by this 
ELISA (Figure 7). There was no sCD14 detected in the void volume of any donors, 
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FIGURE 7. Individual fractions of human plasma separation with sCD14 concentration. For each 
donor, 1 ml of human plasma was run over a S200 column in Ammonium Acetate Buffer, pH 7.0. The 
first 30 ml of buffer were discarded and 1 ml fractions were collected for the next 96 mLs. 
Approximate molecular weights (Blue arrow MWs=75, 44, 29, 13.7kD respectively) were determined 
by running Gel Filtration Calibration kits (GE Healthcare Life Sciences) and calculating a standard 
curve. The odd fractions were analyzed for the presence of sCD14 by ELISA (R&D Systems, 
Minneapolis MN) according to manufacturer instructions. 2 Donors with atypical 280nm 
spectrophotometry are highlighted in yellow and orange. 
 
As a numeric assessment of the symmetry of the sCD14 profile, the total sCD14 
concentration measured in all donors (N=15) on either side of the average peak was 
compared. The average peak was empirically estimated by graphing the mean sCD14 
concentration at each elution volume in all donors (data not shown). The highest mean 
sCD14 concentration was found to be at elution volume 61mL, which corresponds to 
~59kDa. The total sCD14 measured in all donors in the elution volumes that came out 
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before 61mL was 4200ng, while the total sCD14 measured in all donors after elution 
volume 63mL was 3525ng.  
In order to study variation at regions of the sCD14 fractionation profile, average 
measurements from sections of odd elution volumes from each donor were combined into 
‘bins’ that spanned the observed sCD14 fractionation profile in most donors. In order to 
just capture the typical fractionation profile, the first bin and last bins included an elution 
volume if no more than two donors had an sCD14 measurement of 0.00 ng/mL. This 
criterion excluded two elution volumes on the left side of the peak (39mL and 41mL) and 
four elution volumes (79mL, 81mL, 83mL and 85mL) on the right side of the peak from 
being included in bins. 18 elution volumes met the inclusion criterion, and spanned 
evenly from 43mL to 77mL by odd elution volumes. The average measured sCD14 of 
three sequential elution volumes from each donor represented an observation for each 
bin.  
The mean, median, SD and CV of each bin were calculated (Table 2). The median 
and mean total protein content and sCD14 concentration were similar for 5 of the bins. 
The bin containing elution volumes 49mL, 51mL and 53mL had a mean sCD14 
concentration of 22.8ng/mL and a median of 27.6ng/mL, likely capturing that some 
donors had distinct peaks or shoulders between 135kDa and 100kDa. The SD of sCD14 
concentration was lowest at the edges of the peaks and highest in the bin containing 
elution volumes 55mL, 57mL and 59mL, corresponding to a MW range from 87kDa to 
57kDa. The SD did not have a discernible pattern for bins of total protein concentration. 
The bin that captured the approximate sCD14 fractionation peak of all donors, 
determined by the greatest mean and median, was comprised of elution volumes 61mL, 
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63mL and 65mL, corresponding to a MW range from 59kDa to 47kDa. The CV varied 
across the bins of total protein and sCD14 concentration in both atypical-included and 
atypical-excluded groups, but was often the highest in the bins on the edges of the curve. 
Lower CV in the bins with higher mean sCD14 concentrations is likely a reflection of the 
increasing mean, and not of decreasing variation between samples.  
Description	  of	  Variation	  and	  Mean	  of	  Binned	  Elution	  
Volumes	  
sCD14	  Binned	  Elution	  Volumes	  With	  Atypical	  Donors	  Excluded	  
(N=13)	  	   Descriptions	  (ng/mL)	  
Elution	  Volumes	  (mL)	   MW	  (kDA)	   Median	   Mean	   SD	   CV	  
31,33,35	   ≥200kDa	   -­‐	   -­‐	   -­‐	   -­‐	  
37,39,41	   ≥200kDa	   -­‐	   -­‐	   -­‐	   -­‐	  
43,45,47	   ≥200-­‐157kDa	   7.52	   9.08	   4.14	   0.46	  
49,51,53	   135-­‐100kDa	   22.80	   27.55	   9.51	   0.35	  
55,57,59	   87-­‐67kDa	   58.69	   59.12	   13.78	   0.23	  
61,63,65	   59-­‐47kDa	   77.28	   76.40	   10.13	   0.13	  
67,69,71	   42-­‐34kDa	   21.91	   22.68	   6.81	   0.30	  
73,75,77	   30-­‐25kDa	   7.72	   7.50	   2.25	   0.30	  
Total	  Protein	  Binned	  Elution	  Volumes	  With	  Atypical	  Donors	  
Excluded	  	  	  (N=13)	   Descriptions	  (mg/mL)	  
Elution	  Volumes	  (mL)	   MW	  (kDA)	   Median	   Mean	   SD	   CV	  
31,33,35	   ≥200kDa	   0.13	   0.12	   0.04	   0.37	  
37,39,41	   ≥200kDa	   1.75	   1.73	   0.33	   0.19	  
43,45,47	   ≥200-­‐157kDa	   2.33	   2.37	   0.24	   0.10	  
49,51,53	   135-­‐100kDa	   2.79	   2.71	   0.20	   0.07	  
55,57,59	   87-­‐67kDa	   2.53	   2.52	   0.23	   0.09	  
61,63,65	   59-­‐47kDa	   1.41	   1.52	   0.35	   0.23	  
67,69,71	  
42-­‐34kDa	  
0.08	   0.08	   0.03	   0.37	  
73,75,77	   30-­‐25kDa	   0.03	   0.04	   0.02	   0.58	  
TABLE 2. Median, mean standard deviation (SD) and coefficient of variation (CV) for the atypical-excluded 
group (N=13) of the sCD14 concentration and total protein concentration in binned elution volumes. Fractions 
containing the typical detectable sCD14 profile were identified. These elution volumes were used to bin the 
sCD14 concentration and total protein concentration by separately combining the average total protein 
concentration and sCD14 concentration from 3 adjacent fractions from each donor.  
 
Munger	   22	  
Box and whisker plots were used to visualize binned sCD14 concentration (Figure 
8), and total protein concentration (Figure 9). The asymmetry of the fractionation profile 
that was observed in many individual donors (Figure 4) persisted when the data were 
binned (Figure 8). The bins represented the approximate regions of the combined sCD14 
fractionation profile of all samples and visually seemed to show that different regions of 
the profile had different levels of variation. The 2 bins on the edge of the profile showed 
much less variation than the 4 bins capturing the peak and shoulders of the sCD14 
profile. The shoulder bins (49mL-53mL and 67mL-71mL) also showed high variation. 
The bin containing elution volumes 55mL-59mL, corresponding to a MW range from 
87kDa to 67kDa appeared to have the widest variability in sCD14 concentration. The 
higher MW shoulder, corresponding to a MW range between 100kDa to 135kDa 
appeared to have more variation than the lower MW shoulder, which corresponded to a 
MW range from 34kDa to 42kDa. The bins with total protein concentration had some 
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FIGURE 8. Combined fractions of sCD14 concentration of human plasma separation. For each donor, 1 
mL of human plasma was run over a S200 column in Ammonium Acetate Buffer, pH 7.0. The first 30 mL of 
buffer were discarded and 1 ml fractions were collected for the next 96 mLs. Donors with atypical 280nm 
spectrophotometry were excluded. The odd fractions were analyzed for the presence of sCD14 by ELISA 
(R&D Systems, Minneapolis MN) according to manufacturer instructions. Fractions containing the sCD14 
profile were binned by combining the average sCD14 concentration from 3 adjacent fractions from each 
donor and are plotted as a box and whisker with 13 observations per bin. Median and interquartile ranges 
are indicated by the dark band and box edges. The whiskers indicate the 5th and 95th percentiles.  
 
FIGURE 9. For each donor, 1 mL of human plasma was run over a S200 column in Ammonium Acetate 
Buffer, pH 7.0. The first 30 mL of buffer were discarded and 1 ml fractions were collected for the next 96 
mLs and Absorbance at 280 nm was measured using a Nanodrop Spectrophotometer. 2 Donors with 
atypical 280nm spectrophotometry were excluded. Bins contain the average total protein concentration 
from 3 adjacent odd elution volumes from each donor and are plotted as a box and whisker with 13 
observations per bin. The red square indicates the bins where the sCD14 fractionation profile is present as 
measured by ELISA (R&D Systems, Minneapolis, MN). Median and interquartile ranges are indicated by 
the dark band and box edges. The whiskers indicate the 5th and 95th percentiles.  
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The Brown-Forsythe test was used to assess if there were specific bins or groups 
of bins of sCD14 concentrations with statistically different variances using a significance 
of less than 0.01 to account for multiple comparisons. The Brown-Forsythe test is often 
called a modified Levene’s test, as it compares the absolute deviations from the median 
of an empirical distribution of data points. The results of this test are not a reflection of 
the theoretical distribution of the data points, but rather if there are differences of 
variation between 2 or more groups of data points. This test was performed between 
individual bins and groups of multiple bins for sCD14 concentration and for total protein 
concentration (Table 3). Comparisons of variance between bins of total protein 
concentration were used as a method to assess for systemic trends and errors. 
Comparisons of variances of total protein content did not agree with tests between 
variances of binned sCD14 concentration in any discernible pattern, suggesting that 
systemic error was not present.  
Using the Brown-Forsythe test to compare all of the bins to each other found that 
the variances of all of the bins were not equal (P< 6.5E-04). Independently comparing the 
first bin to the last bin found no difference in the variances (P>0.01). The variances of the 
4 bins from elution volumes 49mL to 71mL were compared to each other, finding no 
statistically significant difference (P>0.01). The second bin (135kDa to 100kDa) was 
independently compared to the bin containing elution volumes 87kDa to 67kDa, finding 
an almost statistically significant difference (P=0.0115). The second bin did not have a 
statistically significant variance from the peak bin, which includes a MW range from 
59kDa to 47kDa or to the second to last bin, which includes a MW range from 34kDa to 
42kDa (P>0.05). The bin containing the MW range from 87kDa to 67kDa was 
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independently compared to the bin containing a MW range from 42kDa to 34 kDa, also 
not finding a statistically significant difference (P>0.01). Independently comparing the 
peak bin to the second to last did not observe a statistically significant difference either 
(P>0.01).  
Brown-­‐Forsythe	  Test	  of	  Variance	  Between	  
Individual	  Bins	  and	  Grouped	  Bins	  Containing	  
sCD14	  Concentration	  (ng/mL)	  
	  Compared	  Groups	  	  (Each	  bin	  
contains	  combined	  Elution	  



















P	  Value	   P	  Value	  
	  Bins	  1,2,3,4,5,6	   -­‐	   6.56E-­‐04	   4.78E-­‐05	  
Grouped	  Bins	  (2,3,4)	  to	  	  
Grouped	  Bins	  (1,5,6)	   -­‐	   3.63E-­‐08	   0.08555	  
Bins	  2,3,4,5	   Bins	  1,6	   0.2183	   0.002031	  
Bin	  1	  to	  Bin	  6	   Bins	  2,3,4,5	   0.4429	   0.001683	  
Bin	  2	  to	  Bin	  3	   Bins	  1,4,5,6	   0.01146	   0.9904	  
Bin	  2	  to	  Bin	  4	   Bins	  1,3,5,6	   0.9839	   0.13	  
Bin	  2	  to	  Bin	  5	   Bins	  1,3,4,6	   0.4532	   0.002967	  
Bin	  3	  to	  Bin	  5	   Bins	  1,2,4,6	   0.03152	   0.004508	  
Bin	  4	  to	  Bin	  5	   Bins	  1,2,3,6	   0.04241	   0.0005242	  
TABLE 3. Results of Brown-Forsythe test on binned sCD14 and total protein concentrations for 
atypical-excluded group (N=13). Each bin is the average measurement of 3 elution volumes from each 
donor. Bin 1 is elution volumes 43mL, 45mL and 47mL (MW range of ≥200-­‐157kDa). Bin 2 is elution 
volumes 49mL, 51mL and 53mL (MW range of 135-­‐100kDa). Bin 3 is elution volumes 55mL, 57mL 
and 59mL(MW range of 87-­‐67kDa). Bin 4 is elution volumes 61mL, 63mL and 65mL, (MW range of 
59-­‐47kDa). Bin 5 is elution volumes 67mL, 69mL and 71mL(MW range of 42-­‐34kDa). Bin 6 is elution 
volumes 73mL, 75mL and 77mL(MW range of 30-­‐25kDa). The Brown Forsythe test compares absolute 
deviations from the median in each comparison group. Each row represents a different Brown-
Forsythe test. In some tests individual bins were compared to one another and in other tests multiple 
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Discussion 
 
Using the same ELISA that found a relationship between sCD14 and specific 
SNPs in the CHS, this study detected that sCD14 exists primarily around 55kDa, and 
observed a higher MW form primarily between 75kDa and 87kDa. It is also possible that 
a lower MW form around 30kDa was detected, but at very low concentrations near the 
limit of the ELISA. Forms within these ranges have not been described in the literature. 
These findings were observed in singleton from a small group of healthy donors (N=15), 
and based on measurements of the odd chromatography fractions only. Further study is 
needed to determine the precise forms of sCD14 in human plasma.  
Analysis of Results  
The average sCD14 peak was found between elution volumes 61mL and 63mL, 
which includes a MW range between 52kDa and 59kDa based on the MW standard 
curve. This finding confirms previous studies that also observed sCD14 around this 
molecular weight [9, 14, 15, 19]. The presence of shoulders on either side of the main 
sCD14 peak in most donors strongly suggests that this ELISA detects different molecular 
weight forms of sCD14 in plasma. The sCD14 detected in the higher MW shoulders may 
be more glycosylated and bound to various plasma substrates such as LBP or LPS. The 
sCD14 detected in the lower MW shoulders may exist at multiple cleaved, and less-
glycosylated forms. A wide spectrum of forms and different complexes could explain the 
broad, asymmetric peak. The asymmetry of fractionated sCD14 profiles may suggest that 
there may be more types of variants in the higher molecular weight forms than in the 
lower molecular weight forms, but this cannot be presently confirmed. Microparticles and 
exosomes would exist at very high molecular weights that would be present in the void 
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volume. Because no sCD14 was detected in the void volume, it seems that this ELISA 
does not detect sCD14 on microparticles. It cannot be confirmed, but seems unlikely that 
this ELISA detects sCD14-ST in fractions, which would have been visible in the very 
low MW region around 13kDa. These data suggest that the predominant form of sCD14 
in plasma exists between 52kDa to 59kDa.  
The presence of shoulders on either side of the main sCD14 peak, in particular the 
higher MW shoulder and much lower MW shoulders, suggest novel forms and complexes 
of sCD14 in plasma. Shoulders on the lower molecular weight side were present in 7 
donors. In 4 donors this peak occurred around 46.5kDa, and in 1 donor at 41.5kDa, which 
confirms previous observations of a lower MW sCD14 form due to cleavage or de-
glycosylation [22]. In 5 donors a slight shoulder was observed between 30kDa and 
20kDa. Low MW forms in this range have never been noted in the literature, and may 
represent a novel cleavage form of sCD14 that exists at very low concentrations in human 
plasma, or sCD14-ST that is glycosylated, dimerized or bound to some substrate. 
Because the concentration near 30kDa was near the limit of the assay, this finding is 
uncertain. Shoulders on the higher MW side of the peak were more prominent and 
occurred in 10 donors between 71kDa and 135kDa. These peaks may indicate that a 
range of different MW sCD14 forms dimerize or are bound to various substrates. The 
presence of a higher MW sCD14 form in this range would indicate a novel finding. 
Most of the variation between donors seems to occur at shoulders corresponding 
to specific high and low MW elution volumes, and at the peak. There may be more 
variation between donors in the higher molecular weight regions but this was not strongly 
supported by conservative statistical methods.  
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Techniques  
The similarity between plasma-measured sCD14 in these 15 donors to the CHS 
cohort, and the consistent peak and shoulder features observed in multiple donors 
suggests that the techniques employed in this study are reproducible. The methods used 
to collect these data have advantages and limitations to differentiate which molecular 
weight variants of sCD14 exist in human plasma. The availability of human plasma and 
the high costs of the ELISA limited the number of samples that could be tested. Samples 
tested in duplicate, and measuring every fraction would have provided a more rigorous 
validation of these observations. 
Comparing the sCD14 profiles of multiple donors to each other and to a standard 
curve is prone to variation between runs. The column should theoretically separate 
molecules of the same molecular weight into the same elution volumes for each run. 
Practically there are various technical reasons why each run may not be consistent. For 
instance, once a sample is injected, the fraction collector must be manually started. 
Differences between the start-time of the fraction collector could account for some of the 
observed variation between samples. While unlikely, there could also be mechanical 
differences in the fraction collector or pump between runs. Differences between sample 
runs could cause false conclusions of variation between donors, and could cause an 
incorrect interpretation of molecular weight.  
Because of the potential for one run to elute before or after another, the total 
protein concentration was used as a “standard” of each run. The total protein and sCD14 
fractionation patterns were visually assessed to see if a particular donor’s sCD14 
fractionation profile seemed to come off the column earlier or later than the others. There 
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was no observable indication that a sample eluted of the column significantly earlier or 
later than the other samples, which could have explained the different locations of the 
main sCD14 peak and prominent shoulders. 
It is expected that each elution volume contains proteins spanning multiple 
molecular weights. This assumption is supported by SDS PAGE gel electrophoresis of 
elution volumes across a fractionated plasma sample (Figure 9). This gel showed that the 
column separates protein by MW, eluting high MW proteins before low MW proteins. 
However, each individual elution volume contains a spectrum of high and low molecular 
weight proteins. Interestingly, this gel also shows very low molecular weight proteins in 
the earlier elution volumes and later elution volumes, with no clearly observable pattern. 
These proteins are likely associated with higher MW proteins via ionic interactions that 
are not disrupted by the column or buffer, but would be broken by the SDS buffer used in 
electrophoresis. This observation indicates the challenges of studying the MW forms of 
sCD14 directly in human plasma without introducing experimental conditions that alter 
the in vivo forms. 
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Figure 9. SDS-PAGE gel electrophoresis (Novex	  10%	  Bis-­‐Tris) of elution volumes of 
fractionated plasma. From left to right, the fraction number corresponds to the 
elution volume minus the void volume. These elution volumes are 31mL, 43mL, 
47mL, 51mL, 55mL, 59mL, 61mL, 63mL and 65mL. The 10th lane from the left 
contains 100ng of a recombinant sCD14 standard, lightly detected between 40kDa 
and 50kDa. The 11th lane from the left is pre-stained molecular weight standards, 
and the 12th lane from the left contains a reduced duplicate of elution volume 33mL. 
Proteins were visualized with Cibacron blue dye. 
 
Technical error could have introduced some of the observed variation of 
measured sCD14. There was high variation in sCD14 recovered after chromatography 
compared to the plasma sCD14. A 100% recovery rate of sCD14 in the fractions is not 
practically expected. It is possible that less than 1mL of plasma could have been loaded 
on the column in some cases where a low recovery was observed. The experimental 
procedure involves several steps where the fractions and plasma sample are handled. For 
example, each sample is individually pre-diluted prior to the ELISA. Intra-assay variation 
of the ELISA is another potential reason for the range of recovery rates and could also 
account for some of the apparent variation between samples. Due to the high costs of the 
ELISA, the samples in this study were not measured in duplicate. R&D reports the intra-
assay variation to have a SD between 71pg/mL and 216pg/mL [36]. Each ELISA plate 
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uses a duplicate standard curve to estimate sCD14 concentration of each well. The 
estimated sample sCD14 concentration could vary if the standards were incorrectly 
prepared. Measuring plasma and fraction samples in duplicate would help determine if 
intra-assay or inter-assay variation is a significant contributor to the measured loss of 
sCD14 in the fractions. 
Ultimately, it is unknown which forms of sCD14 the ELISA is actually 
measuring. The capture antibody was raised against a recombinant human CD14 from a 
transfected CHO cell line. The recombinant CD14 is used to generate the standard curve, 
from which the concentrations of sCD14 are inferred. The assay was designed not to 
cross-react with several plasma proteins, but may still cross-react with some other 
unknown soluble receptors. Moreover, while the capture antibody is mapped to the N-
terminus of CD14, there is no evidence that this kit captures all forms of sCD14 present 
in human plasma. Data from this study indicate that this ELISA kit does not detect 
sCD14 on microparticles, or sCD14-ST. 
Future Directions and Techniques 
There are other techniques that could build on these findings by measuring the 
precise forms detected by the ELISA in each elution volume. It is possible that reducing 
the quantity of plasma injected onto the column and reducing the buffer flow rate could 
improve the resolution of plasma separation. As a method to assess if the CD14 epitope 
of the anti-CD14 antibodies used in the ELISA are structural, different running buffers 
that disrupt ionic bonds or reduce samples could be used to run samples over the column 
followed by analysis of fractions by ELISA. A Western Blot could also be used to assess 
for the precise MW differences between samples.  
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Albumin Depletion 
 Soluble albumin is the most abundant protein in human blood, comprising around 
50% of all plasma proteins and existing an approximate molecular weight of 66kDa, 
which is just greater than the main sCD14 peak [37]. As observed in this study, the 
albumin peak overlaps with the sCD14 peak. This creates a two-fold problem for analysis 
of plasma samples and fractions by Western Blot. The high concentration of albumin can 
result in difficulty running the proteins on a gel, and can disrupt transfer to a blot. There 
are various centrifuge chromatography kits available on the market that can remove 
albumin using various proprietary preparations of Cibacron Blue F3GA. One kit that may 
be a viable method is the Affurum Blue kit (Bio-Rad). This would theoretical allow for 
the removal of all albumin from 400uLs of a fraction. The albumin-depleted sample 
could be washed with the ammonium acetate buffer directly into a tube for freeze-drying. 
Validating this kit would employ 280nm spectrophotometry to confirm the loss of total 
protein and the ELISA to measure if sCD14 was non-specifically binding to the Cibacron 
Blue. 
Speed-vac 
The concentration of sCD14 in individual fractions, as measured by ELISA, may 
be too low to detect by Western Blot. Following albumin removal, the samples could be 
frozen and then lyophilized. The ammonium acetate buffer is volatile, and is suitable for 
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Western Blot 
Western Blotting could serve as a validation of the ELISA and determine 
precisely which forms the ELISA is detecting. Multiple anti-sCD14 antibodies, or a stain 
for sugar moieties could be used to probe a western blot of ELISA fractions. A native gel 
could be run and blotted, as a comparison to SDS-PAGE gel electrophoresis, which 
would disrupt ionic bonds, and a reduced gel, which would reduce disulfide bonds. It 
would be expected to find multiple forms of sCD14 in individual elution volumes. Initial 
attempts at western Blots of column fractions and plasma samples with multiple anti-
CD14 antibodies on SDS PAGE yielded little success.  It may be that the antibodies for 
CD14 have structural epitopes. 
Conclusion 
CD14 is one of many acute-phase proteins that exist at different MW variants, and 
the different forms may have implications for disease processes. Current literature 
suggests that sCD14 may exist on a microparticle [20], as a full-length, cleaved or de-
glycosylated form within the 41kD to 57kDa range [5, 14, 19, 38], and as a 13kDa 
cleavage fragment [17]. The data presented here demonstrate the main MW of sCD14 at 
around 55kDa, with lower molecular weight variants, consistent with previous studies 
indicating cleavage and de-glycosylation [13, 23]. There was no clear evidence for 
microparticle associated CD14, or sCD14-ST (MW~13kD).  We did note a previously 
uncharacterized, prominent shoulder at a higher MW, most notably between 75kDa to 
81kD, which requires further study. 
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